Silo Pharma Inc is a biotechnology company focused on leveraging psychedelic compounds and their therapeutic potential to treat various mental health conditions and neurological disorders
By researching and developing innovative drug delivery methods and formulations, the company aims to create effective treatments that can address unmet medical needs in the psychiatric space. Silo Pharma emphasizes collaboration with academic institutions and industry partners to advance its clinical programs and contribute to the evolving landscape of mental health therapies.
Silo Pharma Inc.'s stock (NASDAQSILO) is on the the rise Wednesday following the company's announcement that it has been awarded a U.S. patent for its PTSD treatment titled "Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females."
Silo Pharma stock is rising after announcing a collaboration with Kymanox to develop a subcutaneous insertion device for its SP-26 chronic pain treatment.
Silo Pharma stock soared on high trading volume after announcing a partnership with Resyca BV for developing an intranasal PTSD treatment. The collaboration aims to enhance drug delivery to the brain, for faster therapeutic benefits and improved safety.
Silo Pharma shares surge due to a global license agreement for Alzheimer's drug SPC-14, aiming to utilize the FDA's 505(b)(2) pathway. SPC-14 shows promise in stress reduction and cognitive improvement. SPC-15 also advances for stress-induced disorders and PTSD.
